肠易激综合征
移植
肠道菌群
医学
粪便细菌疗法
内科学
粪便
免疫学
胃肠病学
生物
微生物学
艰难梭菌
抗生素
作者
Giada De Palma,Michael D. J. Lynch,Jun Lü,Vi T. Dang,Yikang Deng,Jennifer Jury,Genevieve Umeh,Pedro Morell Miranda,Marc Pigrau,Sacha Sidani,María Inés Pinto-Sánchez,Vivek M. Philip,Peter G. McLean,Gabriel Moreno‐Hagelsieb,Michael G. Surette,Gabriela E. Bergonzelli,Elena F. Verdú,Philip Britz‐McKibbin,Josh D. Neufeld,Stephen M. Collins,Přemysl Berčík
出处
期刊:Science Translational Medicine
[American Association for the Advancement of Science (AAAS)]
日期:2017-03-01
卷期号:9 (379)
被引量:414
标识
DOI:10.1126/scitranslmed.aaf6397
摘要
Irritable bowel syndrome (IBS) is a common disorder characterized by altered gut function and often is accompanied by comorbid anxiety. Although changes in the gut microbiota have been documented, their relevance to the clinical expression of IBS is unknown. To evaluate a functional role for commensal gut bacteria in IBS, we colonized germ-free mice with the fecal microbiota from healthy control individuals or IBS patients with diarrhea (IBS-D), with or without anxiety, and monitored gut function and behavior in the transplanted mice. Microbiota profiles in recipient mice clustered according to the microbiota profiles of the human donors. Mice receiving the IBS-D fecal microbiota showed a taxonomically similar microbial composition to that of mice receiving the healthy control fecal microbiota. However, IBS-D mice showed different serum metabolomic profiles. Mice receiving the IBS-D fecal microbiota, but not the healthy control fecal microbiota, exhibited faster gastrointestinal transit, intestinal barrier dysfunction, innate immune activation, and anxiety-like behavior. These results indicate the potential of the gut microbiota to contribute to both intestinal and behavioral manifestations of IBS-D and suggest the potential value of microbiota-directed therapies in IBS patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI